Monte Rosa Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of operations and comprehensive loss
| Year ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2023 | 2022 |
| Operating expenses: | ||
| Research and development | $111,272 | $85,061 |
| General and administrative | 32,039 | 27,323 |
| Total operating expenses | 143,311 | 112,384 |
| Loss from operations | (143,311) | (112,384) |
| Other income (expense): | ||
| Interest income | 9,334 | 3,764 |
| Foreign currency exchange gain (loss), net | (930) | 10 |
| Gain on disposal of fixed assets | 24 | 109 |
| Loss on sale of marketable securities | (131) | — |
| Total other income | 8,297 | 3,883 |
| Net loss before income taxes | (135,014) | (108,501) |
| Provision for income taxes | (338) | — |
| Net loss | $(135,352) | $(108,501) |
| Net loss per share attributable to common stockholders—basic and diluted | $(2.63) | $(2.30) |
| Weighted-average number of shares outstanding used in computing net loss per common share—basic and diluted | 51,396,961 | 47,227,370 |
| Comprehensive loss: | ||
| Net loss | $(135,352) | $(108,501) |
| Other comprehensive income (loss): | ||
| Provision for pension benefit obligation | (1,369) | 718 |
| Unrealized gain (loss) on available-for-sale securities | 397 | (449) |
| Comprehensive loss | $(136,324) | $(108,232) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.